QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
one-half of one redeemable warrant |
||||
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
☒ | Smaller reporting company | |||||
Emerging growth company |
Page |
||||
1 | ||||
2 | ||||
3 | ||||
4 | ||||
5 | ||||
16 | ||||
18 | ||||
18 | ||||
19 | ||||
19 | ||||
19 | ||||
19 | ||||
19 | ||||
20 | ||||
20 | ||||
21 |
March 31, 2022 |
December 31, 2021 |
|||||||
(Unaudited) | ||||||||
ASSETS |
||||||||
Current assets |
||||||||
Cash |
$ | $ | — | |||||
Prepaid expenses |
— | |||||||
Total Current Assets |
— | |||||||
Deferred offering costs |
— | |||||||
Marketable securities held in Trust Account |
— | |||||||
TOTAL ASSETS |
$ |
$ |
||||||
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY |
||||||||
Current liabilities |
||||||||
Accrued expenses |
$ | $ | ||||||
Accrued offering costs |
||||||||
Promissory note – related party |
— | |||||||
Total Current Liabilities |
||||||||
Deferred underwriting fee payable |
— | |||||||
Total Liabilities |
||||||||
Commitments (Note 6) |
||||||||
Series A common stock subject to possible redemption; |
— | |||||||
Stockholders’ (Deficit) Equity |
||||||||
Preferred stock, $ |
— | |||||||
Series A common stock, $ - 1 |
— | |||||||
Series B common stock, $ (1) shares issued and outstanding as of March 31, 2022 and December 31, 2021 |
||||||||
Additional paid-in capital |
— | |||||||
Accumulated deficit |
( |
) | ( |
|||||
Total Stockholders’ (Deficit) Equity |
( |
) |
||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY |
$ |
$ |
||||||
(1) | Includes up to per-share amounts have been retroactively restated to reflect the stock split. On January 18, 2022, the underwriters partially exercised their over-allotment option, hence, |
Operation and formation costs |
$ |
|||
|
|
|||
Loss from operations |
( |
) | ||
|
|
|
|
|
Other income (expense): |
||||
Interest income – bank |
||||
Interest earned on marketable securities held in Trust Account |
||||
Unrealized loss on marketable securities held in Trust Account |
( |
) | ||
Compensation expense |
( |
) | ||
|
|
|||
Total other expense, net |
( |
) | ||
|
|
|||
Net loss |
$ |
( |
) | |
|
|
|||
Weighted average shares outstanding of Series A common stock |
||||
|
|
|||
Basic and diluted loss per share, Series A common stock |
$ |
( |
) | |
|
|
|||
Weighted average shares outstanding of Series B common stock |
||||
|
|
|||
Basic and diluted net loss per share, Series B common stock |
$ |
( |
) | |
|
|
Series A Common Stock |
Series B Common Stock |
Additional Paid-in |
Accumulated |
Total Stockholders’ |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
Capital |
Deficit |
Equity (Deficit) |
||||||||||||||||||||||
Balance — December 31, 2021 |
$ |
$ |
$ |
$ |
( |
) |
$ |
|||||||||||||||||||||
Sale of |
— | — | — | — | — | |||||||||||||||||||||||
Forfeiture of Founder Shares |
— | — | ( |
) | — | — | — | — | ||||||||||||||||||||
Compensation Expense – Fair value of assigned founder shares to Apeiron |
— | — | — | — | — | |||||||||||||||||||||||
Fair value of Public Warrants at issuance |
— | — | — | — | — | |||||||||||||||||||||||
Allocated value of transaction costs to Series A common stock |
— | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||
Remeasurement of Series A common stock to redemption amount |
— | — | — | — | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance – March 31, 2022 |
$ | $ | $ | $ | ( |
) | $ | ( |
) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Flows from Operating Activities: |
||||
Net loss |
$ | ( |
) | |
Adjustments to reconcile net income to net cash used in operating activities: |
||||
Interest earned on marketable securities held in Trust Account |
( |
) | ||
Unrealized loss on marketable securities held in Trust Account |
||||
Compensation expense due to advisor |
||||
Changes in operating assets and liabilities: |
||||
Prepaid expenses |
( |
) | ||
Accrued expenses |
||||
Net cash used in operating activities |
( |
) | ||
Cash Flows from Investing Activities: |
||||
Investment of cash into Trust Account |
$ | ( |
) | |
Net cash used in investing activities |
( |
) | ||
Cash Flows from Financing Activities |
||||
Proceeds from sale of Units, net of underwriting discounts paid |
$ | |||
Proceeds from sale of Private Placement Warrants |
||||
Proceeds from promissory note – related party |
||||
Repayment of promissory note – related party |
( |
) | ||
Payment of offering costs |
( |
) | ||
Net cash provided by financing activities |
$ |
|||
Net Change in Cash |
||||
Cash – Beginning of period |
||||
Cash – End of period |
$ |
|||
Non-Cash investing and financing activities: |
||||
Offering costs included in accrued offering costs |
$ | |||
Initial classification of Series A common stock subject to possible redemption |
$ | |||
Deferred underwriting fee payable |
$ | |||
Gross proceeds |
$ | |
||||||
Less: |
||||||||
Proceeds allocated to Public Warrants |
( |
|||||||
Series A common stock issuance costs |
( |
|||||||
Plus: |
||||||||
Remeasurement of carrying value to redemption value |
||||||||
|
|
|||||||
Series A common stock subject to possible redemption, March 31, 2022 |
$ | |||||||
|
|
Three Months Ended March 31, 2022 |
||||||||
Series A |
Series B |
|||||||
Basic and diluted net loss per common stock |
||||||||
Numerator: |
||||||||
Allocation of net loss, as adjusted |
$ | ( |
) | $ | ( |
) | ||
Denominator: |
||||||||
Basic and diluted weighted average shares outstanding |
||||||||
|
|
|
|
|||||
Basic and diluted net loss per common stock |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
• | in whole and not in part; |
• | at a price of $ |
• | upon not less than |
• | if, and only if, the reported last sale price of the Series A common stock equals or exceeds $ |
Level 1: | Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. | |||
Level 2: | Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. | |||
Level 3: | Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. |
March 31, 2022 |
||||||||
Level |
Amount |
|||||||
Assets: |
||||||||
Marketable securities held in Trust Account |
$ |
* | Filed herewith. |
ATLANTIC COASTAL ACQUISITION CORP. II | ||||
Date: May 20, 2022 | By: | /s/ Shahraab Ahmad | ||
Name: | Shahraab Ahmad | |||
Title: | Chief Executive Officer | |||
(Principal Executive Officer) | ||||
Date: May 20, 2022 | By: | /s/ Jason Chryssicas | ||
Name: | Jason Chryssicas | |||
Title: | Chief Financial Officer | |||
(Principal Financial and Accounting Officer) |